Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Assets: 2010-2024

Historic Non-Current Assets for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $117.2 million.

  • OptimizeRx's Non-Current Assets fell 349.69% to $114.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $462.4 million, marking a year-over-year decrease of 781.16%. This contributed to the annual value of $117.2 million for FY2024, which is 907.49% down from last year.
  • As of FY2024, OptimizeRx's Non-Current Assets stood at $117.2 million, which was down 907.49% from $128.9 million recorded in FY2023.
  • OptimizeRx's Non-Current Assets' 5-year high stood at $128.9 million during FY2023, with a 5-year trough of $25.9 million in FY2021.
  • For the 5-year period, OptimizeRx's Non-Current Assets averaged around $67.1 million, with its median value being $36.1 million (2022).
  • In the last 5 years, OptimizeRx's Non-Current Assets skyrocketed by 25729.9% in 2023 and then crashed by 907.49% in 2024.
  • Over the past 5 years, OptimizeRx's Non-Current Assets (Annual) stood at $27.5 million in 2020, then decreased by 5.81% to $25.9 million in 2021, then skyrocketed by 39.43% to $36.1 million in 2022, then skyrocketed by 257.3% to $128.9 million in 2023, then decreased by 9.07% to $117.2 million in 2024.
  • Its Non-Current Assets stands at $117.2 million for FY2024, versus $128.9 million for FY2023 and $36.1 million for FY2022.